UNITY Biotechnology presents Phase 2b data on UBX1325

UNITY Biotechnology will hold a virtual event for investors on March 24, 2025, at 8:00 AM ET. The company plans to discuss results from its Phase 2b ASPIRE study on UBX1325, a treatment for diabetic macular edema (DME). Dr. Robert Bhisitkul from UCSF will join UNITY's management during the event. They will present findings from the 24- and 36-week trials of UBX1325, which is designed to improve vision in patients with DME. UBX1325 is still being tested and is not yet approved for use anywhere. The treatment targets specific proteins to help eliminate senescent cells, which may improve visual symptoms. Earlier studies showed that a single injection of UBX1325 resulted in significant visual improvements over time compared to a placebo. UNITY is focused on developing therapies that can combat aging-related diseases, especially those affecting the eyes and brain. More information can be found on their website and social media channels.